1	Patterns and predictors of COVID-19 vaccine uptake among United States active duty
2	Service members, 2020-2022: Implications for future pandemics
3	Erica Sercy ^{1,2} , Laveta Stewart ^{1,2} , Megan Clare Craig-Kuhn ^{1,2} , Caryn Stern ³ , Brock Graham ³ ,
4	Amber Michel ^{1,2} , Edward Parmelee ^{1,2} , Simon Pollett, ^{1,2} Timothy Burgess ¹ , David R Tribble ¹
5	
6	¹ Infectious Disease Clinical Research Program, Department of Preventive Medicine and
7	Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland. ² Henry
8	M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland.
9	³ Joint Trauma System, Joint Base San Antonio, San Antonio, Texas, USA.
10	Corresponding author:
11	David Tribble, MD, DrPH
12	Science Director, Infectious Disease Clinical Research Program
13	Professor, Department of Preventive Medicine and Biostatistics
14	Uniformed Services University of the Health Sciences
15	4301 Jones Bridge Rd, Bethesda, MD 20814
16	david.tribble@usuhs.edu, 240-694-2984
17	Word count: 2,928
18	Conflict of interest: The Uniformed Services University (USU) Infectious Diseases Clinical
19	Research Program (IDCRP), a US Department of Defense institution, and the Henry M. Jackson
20	Foundation (HJF) were funded under a Cooperative Research and Development Agreement to
21	conduct an unrelated phase III COVID-19 monoclonal antibody immunoprophylaxis trial
22	sponsored by AstraZeneca. The HJF, in support of the USU IDCRP, was funded by the

2

23	Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological,
24	and Nuclear Defense to augment the conduct of an unrelated phase III vaccine trial sponsored by
25	AstraZeneca. Both trials were part of the U.S. Government COVID-19 response. Neither is
26	related to the work presented here.
27	Financial disclosure: Support for this work was provided by the Infectious Disease Clinical
28	Research Program (IDCRP), a Department of Defense program executed through the Uniformed
29	Services University of the Health Sciences, Department of Preventive Medicine and Biostatistics
30	through a cooperative agreement with The Henry M. Jackson Foundation for the Advancement
31	of Military Medicine, Inc. (HJF). This project has been funded by the National Institute of
32	Allergy and Infectious Diseases, National Institutes of Health, under Inter-Agency Agreement
33	Y1-AI-5072, and the Defense Health Program, U.S. DoD, under award HU0001190002.

34

3

36 Abstract

37	Introduction. Vaccine mandates have been used to minimize the duty days lost and deaths
38	attributable to infectious disease among active duty Service members (ADSMs). In response to
39	the global COVID-19 pandemic, in August 2021, the United States Department of Defense
40	issued a COVID-19 vaccine mandate for all ADSMs. This study aimed to investigate COVID-19
41	vaccine uptake among the ADSM population, as well as factors associated with timing of
42	COVID-19 vaccine receipt.
43	Methods: This study included ADSMs on active duty between 1/1/2020-6/30/2022. Univariate
44	analyses investigated associations between demographic factors (age, sex, race, ethnicity, branch
45	of service, rank, state of residence) and COVID-19 diagnosis with the following outcomes: 1)
46	time to primary series initiation in relation to the DoD vaccine mandate, 2) time between doses
47	of the two-dose primary series, and 3) time between booster eligibility and receipt
48	Results: A total of 1,799,466 ADSMs were included, with 90% receiving \geq 1 COVID-19 vaccine
49	dose during the study period and 77% initiating the primary series prior to the mandate. Over
50	80% of ADSMs received a complete primary series, with 96% of those adhering to the
51	recommended regimen. History of COVID-19 diagnosis was associated with later receipt of all
52	doses.
53	Conclusions: COVID-19 vaccine uptake was high among all ADSMs, with the majority
54	initiating the primary series before the mandate. The high vaccine uptake among ADSMs shown

here may be used as a guide to both military and civilian pandemic policy and outreach efforts
related to enhanced vaccine uptake.

4

58 Introduction

59 Historically, the United States (U.S.) military system has required specific vaccinations to aid in combat readiness and preserve health.^{1,2} During the 1918 influenza pandemic, ~20-40% of U.S. 60 Army and Navy personnel experienced symptomatic illness, associated with ~8.7 million lost 61 duty days and 26,000 deaths.³ In response, an influenza vaccination requirement was issued in 62 63 1945 for all military personnel, and similar requirements have continued to be issued to cover the 64 vaccine schedule recommended by the U.S. Centers for Disease Control and Prevention (CDC) and in response to emerging infectious agents.^{3,4} Vaccines currently required by the U.S. 65 66 Department of Defense (DoD) for all Service members prior to entry or at accession include 67 adenovirus, hepatitis A, hepatitis B, influenza, measles/mumps/rubella (MMR), meningococcal, tetanus-diphtheria (Tdap), and varicella.^{1,4,5} Periodic administration of other vaccines is required 68 69 in specific risk-based circumstances, including yellow fever, typhoid, Japanese encephalitis, and polio, as well as annual influenza vaccination.⁶ Prior to the COVID-19 pandemic, all vaccines 70 required by the DoD had full U.S. Food and Drug Administration (FDA) approval.^{4,5} 71 The first case of COVID-19 was reported in November 2019 in Wuhan, China, followed by 72 rapid spread worldwide.⁷ Development of a COVID-19 vaccine began in late March 2020.⁸ 73 74 leading to the first Emergency Use Authorization (EUA) by the FDA in mid-December 2020 for a two-dose vaccine series, with additional EUAs subsequently being granted to several other 75 vaccine products.⁹⁻¹¹ Between January 2020 and August 2021, there were ~190,000 COVID-19 76 cases among active duty and Reserve/Guard Service members.¹² By July 2021, even in the 77 absence of FDA approval, a large percentage (~67%) of the active duty population had received 78 at least one dose of a COVID-19 vaccine.¹³ Following the first FDA approval of a COVID-19 79 vaccine on 23 August 2021 (Pfizer),¹⁴ the DoD issued a mandate on 24 August 2021 that all 80

5

active duty Service members must be vaccinated against COVID-19 or face discharge to "protect
the health and readiness of the force."¹⁵ In September 2021, the first EUA for a booster dose was
issued.¹⁶

Despite high levels of early uptake of the COVID-19 vaccine among active duty Service 84 members, several challenges to full vaccination have presented. In surveys of military personnel, 85 86 20-40% reported COVID-19 vaccine hesitancy, noting concerns about "short-term side effects," "long-term side effects," "vaccine effectiveness," "being infected with COVID-19 from the 87 vaccine," "worry about misinformation/political agenda," and "lack of trust in the 88 government."^{17–19} In addition, because two of the three most commonly available vaccines in the 89 90 U.S. in the early pandemic comprised a two-dose series (Pfizer, Moderna), attrition after the first dose led to incomplete vaccination: as of May 11, 2023, 81% of the general U.S. population had 91 received at least one dose, but only 70% completed a two-dose primary series.²⁰ To inform 92 93 preparedness plans for future vaccine-preventable infectious threats, this study aimed to describe the patterns and predictors of COVID-19 vaccine receipt among active duty Service members in 94 95 the Military Health System (MHS).

96 Methods

97 Study Population and Variables

Data without personal identifiers were from the MHS Data Repository (MDR), a claims-based
centralized repository that includes healthcare data on all beneficiaries of the MHS, including
active duty Service members, Reserve/Guard members, veterans/retirees, and dependents. This
research received an exempt determination by the Uniformed Services University of the Health
Sciences Human Research Protection Program.

6

103	This study included active duty Service members and Reserve/Guard members on active duty
104	(collectively ADSMs) at any time in 1/1/2020-6/30/2022. Individuals were excluded if they had
105	missing age or age <17 or >65. Only ADSMs who received all doses from products with EUAs
106	in the U.S. (Pfizer, Moderna, Janssen/Johnson & Johnson) were included. Individuals were
107	excluded if they met any of the following conditions that suggested documentation error: 1) a
108	first recorded dose date prior to the EUA date (Pfizer: 12/11/2020; Moderna: 12/18/2020;
109	Janssen/Johnson & Johnson: 2/27/2021); 2) booster dates prior to the first booster EUA (Pfizer:
110	9/22/2021); 3) <17 days between primary series doses (Pfizer, Moderna); or 4) <5 months (150
111	days, Pfizer, Moderna) or <2 months (60 days, Janssen/Johnson & Johnson) between completion
112	of the primary series and the first booster (Supplementary Figure 1).
113	The following variables were collected on all individuals: demographics (age, sex, race,
114	ethnicity, branch of service, rank, state of residence), all COVID-19 vaccine doses (date,
115	manufacturer), and COVID-19 diagnosis (infection criteria met, diagnosis date). State of
116	residence was defined using permanent residence for Reserve/Guard members and assigned unit
117	location for individuals on active duty; residence was measured at COVID-19 diagnosis date for
118	those with infection during the study period and most recent address (end of study period or end
119	of active duty) for individuals with no COVID-19 diagnosis during the study period. COVID-19
120	diagnosis was defined as either lab confirmed, i.e., documented positive PCR or antigen test, or
121	using ICD-10-CM codes (Supplementary Table 1). The index date of infection was the first date
122	meeting either lab or ICD-10-CM criteria; for individuals with multiple COVID-19 diagnoses,
123	only the earliest diagnosis date was considered.
124	A high degree of collinearity was detected between state of residence and multiple other

125 variables (race, branch of service, rank) in the dataset. It is likely that much of the collinearity

7

126	between state of residence and branch of service is attributable to the differential presence of
127	military bases in each state (Supplementary Figure 2). Because previous studies have reported
128	wide geographic variation in COVID-19 waves, variants, and vaccination rates across the
129	U.S., ^{21–23} it was determined that state of residence should be retained as a variable in the final
130	analyses. Therefore, to account for collinearity, findings are reported overall and stratified by
131	state of residence. Only results for select states with the largest ADSM populations are displayed
132	in the stratified analyses.

133 Statistical Analyses

134 Associations of demographics and COVID-19 diagnosis with the following outcomes were examined: 1) initiation of the primary series in relation to the DoD COVID-19 vaccine mandate, 135 2) completion of a two-dose primary series in the manufacturer-recommended timeframe, and 3) 136 days between booster eligibility and receipt. Timing of primary series initiation was defined as 137 receipt of a first COVID-19 vaccine primary series dose prior to compared to after the DoD 138 139 mandate. Timing of primary series completion was defined as occurring within the period 140 recommended by the vaccine manufacturer (Pfizer or Moderna; <56 days between the first and second dose) compared to late (>56 days). An individual's booster eligibility date was defined as 141 142 the later of the following: 1) 22 September 2021 (the EUA for the first booster) or 2) the completion date of the primary series plus 5 months (Pfizer or Moderna primary series) or 2 143 months (Janssen/Johnson & Johnson primary dose). Univariate associations with each outcome 144 were assessed in the population overall and stratified by state of residence using chi-square tests, 145 Mann-Whitney U tests, and unadjusted logistic or generalized linear regression modeling. 146 Adjusted regression analyses were not performed because of multicollinearity that remained in 147

8

148 multivariable models after stratifying by state of residence. All statistical analyses were

149 conducted using SAS Studio (SAS Institute, Inc., Cary, NC).

150 **Results**

151 The study population included 1,799,466 ADSMs. Most of the population was age 17-49 (98%), 152 male (82%), white (71%), non-Hispanic (83%), an enlisted-level Service member (83%), and in 153 the Army (39%), Navy (23%), or Air Force (22%) (Supplementary Table 2). The seven states with the largest ADSM populations were California (12% of the full population), Texas (9%), 154 Virginia (8%), North Carolina (7%), Georgia (5%), Florida (5%), and Washington (4%). In the 155 156 full population, 23% of ADSMs received a complete primary COVID-19 vaccine series and at 157 least one booster, 61% received a complete primary series with no booster, 5% received an incomplete primary series, and 10% had no record of receiving one of the three COVID-19 158 159 vaccine products evaluated here (Table 1). Florida (90%) and Virginia (90%) had the highest percentages of individuals who received a complete primary series, followed by Washington 160 161 (86%), California (84%), North Carolina (83%), Texas (83%), and Georgia (82%) (P<0.0001). Among the 1,594,948 ADSMs who initiated a primary series, 77% initiated prior to the DoD 162 mandate (Figure 1 and Table 1). Primary initiation timing differed by state of residence, with 163 164 Washington (85%), Virginia (80%), and California (78%) having the highest percentages of residents initiating prior to the mandate. Individual-level factors significantly associated with 165 initiation of the primary series prior to the mandate included older age (OR=2.46, 95% CI 2.38-166 2.54), female sex (OR=1.04, 95% CI 1.03-1.05), American Indian or Alaska Native (OR=1.06, 167 95% CI 1.02-1.10), Asian or Pacific Islander (OR=2.02, 95% CI 1.98-2.05), or other (OR=1.34, 168 95% CI 1.32-1.37) race compared to white, Hispanic ethnicity (OR=1.03, 95% CI 1.02-1.04), 169 170 Coast Guard (OR=1.54, 95% CI 1.50-1.58) or Navy (OR=1.54, 95% CI 1.52-1.55) branch of

171	service compared to Army, and officer (OR=4.28, 95% CI 4.22-4.35) or warrant officer
172	(OR=2.03, 95% CI 1.96-2.10) rank compared to enlisted (Table 2 and Supplementary Table 3).
173	Black or African American (OR=0.75, 95% CI 0.74-0.76) race, Air Force (OR=0.88, 95% CI
174	0.87-0.89) or Marine Corps (OR=0.58, 95% CI 0.57-0.59) branch of service, and COVID-19
175	diagnosis prior to initiating the primary series (OR=0.55, 95% CI 0.54-0.55 for lab confirmed,
176	OR=0.51, 95% CI 0.50-0.52 for ICD-10-CM defined) were associated with lower odds of
177	initiating before the mandate. The higher odds of pre-mandate initiation for older ADSMs, Asian
178	or Pacific Islanders, and officer or warrant officers held across all states; likewise, the lower odds
179	of pre-mandate initiation for blacks or African Americans, those in the Marine Corps, and those
180	with a COVID-19 diagnosis prior to initiating the primary series held across all seven states
181	(Table 2 and Supplementary Table 4).
182	Among those ADSMs who completed a two-dose primary series, 96% received the second dose
183	within the recommended timeframe (Table 1). The percentage of ADSMs completing their
184	primary series in the recommended time differed significantly by state, ranging from a low of
185	95% in Texas to a high of 97% in Virginia, Florida, and Washington. Female sex (OR=1.04,
186	95% CI 1.02-1.06), Asian or Pacific Islander (OR=1.19, 95% CI 1.15-1.24), and other (OR=1.25,
187	95% CI 1.20-1.30) race compared to white, Air Force (OR=1.33, 95% CI 1.30-1.36), Coast
188	Guard (OR=1.07, 95% CI 1.02-1.13), Marine Corps (OR=1.17, 95% CI 1.14-1.20), and Navy
189	(OR=1.80, 95% CI 1.76-1.85) branch of service compared to Army, and officer (OR=1.44, 95%
190	CI 1.41-1.48) rank compared to enlisted had higher odds of completing the primary series in the
191	recommended timeframe (Supplementary Tables 3 and 5). Black or African American race
192	(OR=0.90, 95% CI 0.88-0.92) and a COVID-19 diagnosis between the first and second primary
193	doses (lab confirmed, OR=0.23, 95% CI 0.21-0.24; ICD-10-CM defined, OR=0.23, 95% CI

10

0.22-0.25) were associated with lower odds of completing the second primary dose in the
recommended time. The lower odds of primary series completion in the recommended time for
COVID-19 diagnosis between primary doses held across all seven states (Supplementary Tables
5 and 6).

Among ADSMs who completed a primary series and received at least one booster, the median 198 199 time between booster eligibility and receipt was 90 days (Table 1). This median time was 200 significantly different across states, ranging from 85 days in Texas to 98 days in California and 201 Washington. Individual factors associated with shorter time between eligibility and receipt 202 included older age (the older age group got their booster a mean of 18.78, 95% CI 17.96-19.59, 203 days before the younger group), female sex (5.93, 95% CI 5.53-6.33, days before males), other race (0.81, 95% CI 0.16-1.47, day before whites), Coast Guard (6.72, 95% CI 5.71-7.73, days 204 205 before Army) branch of service, and officer (16.13, 95% CI 15.78-16.49, days before enlisted) or 206 warrant officer (7.86, 95% CI 6.71-9.01, days before enlisted) rank (Table 3 and Supplementary 207 Table 3). Factors associated with longer time between booster eligibility and receipt included 208 American Indian or Alaska Native race (4.23, 95% CI 2.58-5.87, days after whites), Hispanic 209 ethnicity (4.20, 95% CI 3.76-4.65, days after non-Hispanics), Air Force (0.69, 95% CI 0.28-1.10, 210 days after Army), Marine Corps (18.21, 95% CI 17.51-18.91, days after Army) and Navy (7.74, 95% CI 7.33-8.16, days after Army) branch of service, and COVID-19 diagnosis between 211 completion of the primary series and the booster (40.72, 95% CI 40.07-41.36, days after the no-212 213 infection group for lab confirmed; 22.49, 95% CI 21.61-23.37, days after the no-infection group 214 for ICD-10-CM defined). The associations of older age and female sex with fewer days between 215 booster eligibility and receipt and the associations of COVID-19 diagnosis between the primary

11

series and booster with longer time between eligibility and receipt were consistent across allstates (Table 3 and Supplementary Table 7).

218 **Discussion**

In this study, which aimed to evaluate U.S. military deployment of the COVID-19 vaccine during the pandemic, results showed that most of the ADSMs who initiated a COVID-19

primary series did so prior to the DoD vaccine mandate, at over three-fourths (77%) of the

population reported here. The mandate resulted in a further substantial increase, with 87% of the

population initiating by the end of December 2021 and 90% at the end of the study period

224 (Figure 1). This is higher than in the overall adult U.S. population, where ~78% of individuals

had received at least one vaccine dose by the end of the study period (30 June 2022).²⁰

Trends in vaccine uptake varied over time between the overall U.S. and ADSM populations.

Both groups showed a large spike in primary series initiation soon after the EUAs in January-

April 2021 (Figure 1).²⁰ However, initiation among ADSMs thereafter showed a single notable

spike after the DoD mandate in August 2021 (Figure 1). Trends in overall U.S. vaccine initiation

appeared to be more responsive to COVID-19 variant waves,²⁴ with later peaks in initiation

corresponding to the Delta (June-November 2021) and early Omicron (December 2021-February

232 2022) waves in the U.S.²⁵ The ADSM population did not show similar responses to these waves,

although the DoD mandate was issued during the Delta wave in the U.S., and so the peak in

initiation after the mandate may have been affected by both factors.

235 Some associations of demographic factors with vaccine timing outcomes were consistent across

all states, such as the increased odds of higher-ranking ADSMs initiating their primary series

before the mandate, completing their second dose in the recommended time, and receiving their

12

238	booster closer to their eligibility date. Additionally, COVID-19 diagnosis during a relevant
239	timeframe was consistently associated with less-favorable vaccine metrics. However, this delay
240	is consistent with CDC recommendations, stating that individuals should not receive a COVID-
241	19 vaccine during active COVID-19 disease and should delay their vaccine until after their
242	isolation period is over: 7-10 days after symptom onset or first positive test and up to 20 days for
243	those with severe illness. ²⁶ The CDC additionally suggested during the early pandemic that
244	individuals consider delaying COVID-19 vaccination until 3 months after symptom onset or a
245	first positive test, in an effort to preserve vaccine supply and capitalize on natural immunity from
246	infection. ²⁷
247	Other associations varied by state, likely reflecting complex factors that interact to influence

vaccination behavior, including differential vaccine messaging and deadlines within each branch
of service, ²⁸ overall vaccine messaging and environment by state, ^{29–31} and requirements related
to deployment, ³² among many other secular factors (e.g., issues with vaccine supply shortages in
certain regions). ^{33,34}

In a complementary manuscript, Dullea et al. (unpublished observations) described demographic 252 factors in the ADSM population associated with completion of the COVID-19 primary vaccine 253 254 series after the DoD mandate compared to those who remained unvaccinated in 12/11/2020-255 1/1/2022. Their findings showing an association between history of COVID-19 infection and 256 unvaccinated status mirror the findings reported here. Further, Dullea et al. found that ADSMs 257 who completed their series in response to the mandate were more likely to be black or African 258 American, Hispanic, male, or of officer rank compared to those who remained unvaccinated. As our findings here reported that ADSMs who were black or African American, Hispanic, or male 259 260 were less likely to initiate their primary series pre-mandate, the Dullea et al. manuscript shows

13

261	that the DoD mandate "picked up" those individuals who did not initiate pre-mandate and
262	reduced disparities in vaccine status across demographic factors by the end of the observation
263	period, further emphasizing the effectiveness of the mandate among this population.
264	Limitations of COVID-19 vaccine data include highly variable vaccine availability and
265	eligibility for the primary series and boosters over the course of the pandemic. For example,
266	these analyses considered booster eligibility as the later of 22 September 2021 (the first booster
267	EUA) or 5 months after primary series completion. However, on 22 September 2021, the Pfizer
268	booster was recommended only for select high-risk individuals. ³⁵ Therefore, most of the young,
269	healthy population included here was likely not recommended to receive a booster dose on this
270	date; however, to standardize analyses, this EUA date was utilized as the booster eligibility date
271	across the population. This likely resulted in overestimation of times between booster eligibility
272	and receipt.

273 Conclusions

274 Vaccine development during the COVID-19 pandemic proceeded at an extraordinarily rapid 275 pace, with EUAs issued only ~9 months after the official start of the pandemic. The DoD has 276 historically required select vaccines among ADSMs, but these requirements have applied to 277 vaccines with full FDA approval. The findings here showed that ADSMs were highly responsive 278 to seeking COVID-19 vaccination during the EUA period, prior to FDA approval. The DoD 279 COVID-19 vaccine mandate was subsequently successful at further raising the already high 280 coverage among ADSMs. Overall, although uptake differed significantly by branch of service, 281 rank, and state of residence, the data described here indicate an effective vaccine implementation effort by the DoD during the COVID-19 pandemic, leading to COVID-19 vaccine coverage that 282

14

exceeded coverage in the civilian population, as well as earlier uptake than the overall U.S.

- 284 population.
- 285

286 Acknowledgements

- 287 Support for this work was provided by the Infectious Disease Clinical Research Program
- 288 (IDCRP), a Department of Defense program executed through the Uniformed Services
- 289 University of the Health Sciences, Department of Preventive Medicine and Biostatistics through
- a cooperative agreement with The Henry M. Jackson Foundation for the Advancement of
- 291 Military Medicine, Inc. (HJF). This project has been funded by the National Institute of Allergy
- and Infectious Diseases, National Institutes of Health, under Inter-Agency Agreement Y1-AI-
- 5072, and the Defense Health Program, U.S. DoD, under award HU0001190002.

294 **References**

295	1.	Ratto-Kim S, Yoon IK, Paris RM, Excler JL, Kim JH, O'Connell RJ. The US military
296		commitment to vaccine development: A century of successes and challenges. Front
297		Immunol. 2018;9:1397.
298	2.	Ho ZJM, Hwang YFJ, Lee JMV. Emerging ang re-emerging infectious diseases:
299		Challenges and opportunities for militaries. Mil Med Res. 2014;1:21.
300	3.	Byerly CR. The U.S. military and the influenza pandemic of 1918-1919. Public Health
301		<i>Rep</i> . 2010;125(Suppl 3):82-91.
302	4.	Elliott BP, Chambers S. A historical analysis of vaccine mandates in the United States
303		military and its application to the COVID-19 vaccine mandate. Vaccine.
304		2022;40(51):7500-7504.
305	5.	Yang YT, Reiss DR. Military Vaccinations. In: Vaccine Law and Policy. 1st ed. Springer
306		Cham; 2023:185-191.
307	6.	Defense Health Agency Military Health System. Immunization healthcare division.
308		Published April 5, 2024. Accessed April 11, 2024. https://health.mil/Military-Health-
309		Topics/Health-Readiness/Immunization-Healthcare
310	7.	Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed.
311		2020;91(1):157-160.
312	8.	Le TT, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape.
313		Nat Rev Drug Discov. 2020;19(5):305-306.

- 9. US Food & Drug Administration. FDA takes key action in fight against COVID-19 by
- issuing emergency use authorization for first COVID-19 vaccine.
- 316 https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-
- 317 against-covid-19-issuing-emergency-use-authorization-first-covid-19.
- 10. US Food & Drug Administration. FDA takes additional action in fight against COVID-19
- by issuing emergency use authorization for second COVID-19 vaccine.
- 320 https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-
- 321 against-covid-19-issuing-emergency-use-authorization-second-covid.
- 11. US Food & Drug Administration. FDA issues emergency use authorization for third
- 323 COVID-19 vaccine. https://www.fda.gov/news-events/press-announcements/fda-issues 324 emergency-use-authorization-third-covid-19-vaccine.
- 12. Stahlman S, Hiban K, Mahaney H, Ford S. Incident COVID-19 infections, active and
- reserve components, 1 January 2020-31 August 2021. *MSMR*. 2021;28(12):14-21.
- Accessed October 22, 2023. https://health.mil/News/Articles/2021/12/01/Incident-Cov MSMR
- 13. Losey S. Biden orders military to move toward mandatory COVID vaccine.
- 330 https://www.military.com/daily-news/2021/07/29/biden-orders-military-move-toward-
- 331 mandatory-covid-vaccine.html.
- 14. US Food & Drug Administration. FDA approves first COVID-19 vaccine.
- 333 https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-
- 334 vaccine.

335	15.	Vergun D. Secretary of Defense mandates COVID-19 vaccinations for Service members.
336		US Department of Defense News. Published August 25, 2021. Accessed January 28,
337		2024. https://www.defense.gov/News/News-Stories/Article/Article/2746111/secretary-of-
338		defense-mandates-covid-19-vaccinations-for-service-members/
339	16.	US Food & Drug Administration. FDA authorizes booster dose of Pfizer-BioNTech
340		COVID-19 vaccine for certain populations. https://www.fda.gov/news-events/press-
341		announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-
342		populations.
343	17.	Theis SR, Li PC, Kelly D, et al. Perceptions and concerns regarding COVID-19
344		vaccination in a military base population. Mil Med. 2021;187(Special Issue 13):e1503-
345		e1508.
346	18.	Higginson JD, Tumin D, Kuehhas TC, et al. COVID-19 vaccine hesitancy among
347		deployed personnel in a joint environment. Mil Med. 2023;188(1-2):e32-e36.
348	19.	Nguyen KH, Mansfield KA, Xie CY, Corlin L, Niska RW. COVID-19 adult, childhood,
349		and adolescent vaccination coverage among military and civilian families, United States.
350		Mil Med. 2023;188(7-8):e2651-e2660.
351	20.	US Centers for Disease Control and Prevention. COVID Data Tracker: COVID-19
352		vaccinations in the United States. https://covid.cdc.gov/covid-data-
353		tracker/#vaccinations_vacc-people-booster-percent-pop5.
354	21.	Jones B, Kiley J. The changing geography of COVID-19 in the U.S. Pew Research
355		Center. Published December 8, 2020. Accessed April 23, 2024.
356		https://www.pewresearch.org/politics/wp-

357		content/uploads/sites/4/2020/12/PP_2020.12.08_COVID-19-Deaths-Geography_Data-
358		Essay.pdf
359	22.	Zhang S, Liu L, Meng Q, Zhang Y, Yahg H, Xu G. Spatiotemporal patterns of the
360		Omicron wave of COVID-19 in the United States. Trop Med Infect Dis. 2023;8(7):349.
361	23.	Jones B. The changing political geography of COVID-19 over the last two years. Pew
362		Research Center. Published March 3, 2022. Accessed April 23, 2024.
363		https://www.pewresearch.org/politics/2022/03/03/the-changing-political-geography-of-
364		covid-19-over-the-last-two-years/
365	24.	Centers for Disease Control and Prevention. Trends in number of COVID-19 vaccinations
366		in the US. Published May 11, 2023. Accessed January 28, 2024.
367		https://covid.cdc.gov/covid-data-tracker/#vaccination-trends
368	25.	Hodcroft EB. CoVariants: SARS-CoV-2 mutations and variants of interest. Published
369		2021. Accessed January 28, 2024. https://covariants.org/
370	26.	Centers for Disease Control and Prevention. Ending isolation and precautions for people
371		with COVID-19: Interim guidance. Published August 22, 2023. Accessed January 28,
372		2024. https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-
373		isolation.html#anchor_1631644826603
374	27.	Centers for Disease Control and Prevention. Use of COVID-19 vaccines in the United
375		States: Interim clinical considerations. Published April 4, 2024. Accessed April 11, 2024.
376		https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

377	28.	Kaufman E, Lieberman O. US military branches set deadline for members to be
378		vaccinated against Covid-19. CNN. Published September 14, 2021. Accessed January 28,
379		2024. https://www.cnn.com/2021/09/14/politics/us-military-sets-vaccine-dates/index.html
380	29.	Bonner KE, Vashist K, Abad NS, et al. Behavioral and social drivers of COVID-19
381		vaccination in the United States, August-November 2021. Am J Prev Med.
382		2023;64(6):865-876.
383	30.	Santibanez TA, Singleton JA, Black CL, et al. Sociodemographic factors associated with
384		receipt of COVID-19 vaccination and intent to definitely get vaccinated, adults aged >=18
385		years - Household Pulse Survey, United States, April 28-May 10, 2021. CDC
386		AdultVaxView. Published online June 15, 2021. Accessed January 28, 2024.
387		https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-
388		resources/sociodemographic-factors-covid19-vaccination.html#print
389	31.	Roberts-McCarthy E, Buck PO, Smith-Ray RL, et al. Factors associated with receipt of
390		mRNS-1273 vaccine at a United States national retail pharmacy during the COVID-19
391		pandemic. Vaccine. 2023;41(29):4257-4266.
392	32.	Cameron-Blake E, Tatlow H, Andretti B, et al. A panel dataset of COVID-19 policies in
393		185 countries. Nat Hum Behav. 2023;7:1402-1413.
394	33.	Stanley-Becker I, Sun LH. "Pixie dust": Why some vaccine sits on shelves while
395		shortages intensify nationwide. Washington Post.
396		https://www.washingtonpost.com/health/2021/01/21/vaccine-rollout-states-shortages/.
397		Published January 21, 2021. Accessed January 28, 2024.

- 398 34. Liu K, Lou Y. Optimizing COVID-19 vaccination programs during vaccine shortages.
- 399 *Infect Dis Model*. 2022;7(1):286-298.
- 400 35. US Department of Health and Human Services. Secretarial directive on eligibility to
- 401 receive particular COVID-19 vaccine boosters. Published September 25, 2021. Accessed
- 402 July 8, 2024. https://www.hhs.gov/sites/default/files/secretarial-directive-eligibility-covid-
- 403 19-vaccine-boosters.pdf

Figure titles and legends

Figure 1. Monthly frequency of COVID-19 vaccine initiation

	All	California	Texas	Virginia	North Carolina	Georgia	Florida	Washington	P ^a
	N=1,779,466	N=213,128	N=162,709	N=146,939	N=124,573	N=84,380	N=83,156	N=76,683	
Vaccine history									< 0.0001
Complete primary	415,359	40,689	30,439	38,632	16,341	12,957	17,822	17,678	-
series, ≥1 booster	(23.3%)	(19.1%)	(18.7%)	(26.3%)	(13.1%)	(15.4%)	(21.4%)	(23.1%)	
Complete primary	1,082,882	139,186	103,903	93,209	87,201	55,906	57,223	48,164	
series, no booster	(60.9%)	(65.3%)	(63.9%)	(63.4%)	(70.0%)	(66.3%)	(68.8%)	(62.8%)	Áll r
Incomplete primary	96,707	8,534	11,294	2,838	3,483	4,882	2,076	3,132	ights
series	(5.4%)	(4.0%)	(6.9%)	(1.9%)	(2.8%)	(5.8%)	(2.5%)	(4.1%)	s res
No record of	184,518	24,719	17,073	12,260	17,548	10,635	6,035	7,709	erve
vaccination	(10.4%)	(11.6%)	(10.5%)	(8.3%)	(14.1%)	(12.6%)	(7.3%)	(10.1%)	ed. N
ADSMs who initiated a primary series ^b	N=1,594,948	N=188,409	N=145,636	N=134,679	N=107,025	N=73,745	N=77,121	N=68,974	vo reuse
Primary series initiation iming ^c									<0.0001
Pre-mandate	1,230,623 (77.2%)	147,271 (78.2%)	108,818 (74.7%)	108,256 (80.4%)	75,147 (70.2%)	55,405 (75.1%)	56,734 (73.6%)	58,248 (84.5%)	d withou
Post-mandate	364,325 (22.8%)	41,138 (21.8%)	36,818 (25.3%)	26,423 (19.6%)	31,878 (29.8%)	18,340 (24.9%)	20,387 (26.4%)	10,726 (15.6%)	ut permis
ADSMs who completed									sior
two-dose primary series ^d	N=1,444,775	N=171,978	N=131,004	N=124,257	N=98,234	N=66,499	N=70,350	N=60,715	-
Primary series completion timing ^e									<0.0001
Recommended	1,389,085 (96.2%)	165,245 (96.1%)	124,558 (95.1%)	120,944 (97.3%)	94,342 (96.0%)	63,816 (96.0%)	68,325 (97.1%)	60,715 (97.0%)	
Late	55,690 (3.9%)	6,733 (3.9%)	6,446 (4.9%)	3,313 (2.7%)	3,892 (4.0%)	2,683 (4.0%)	2,025 (2.9%)	1,862 (3.0%)	

Table 1. Vaccine status, overall and in select states of residence

ADSMs who received ≥1 booster dose following brimary series completion	N=415,359	N=40,689	N=30,439	N=38,632	N=16,341	N=12,957	N=17,822	N=17,678	
Fime from booster eligibility to receipt (days), median (IQR)	90 (68-120)	98 (71-125)	85 (59-115)	88 (63- 118)	94 (63-127)	96 (70- 125)	95 (70-120)	98 (72-121)	<0.0001

^aP values are for comparisons across the seven states listed in the table. ^bIncludes those who initiated either a one-dose or two-dose

primary series. ^cPre-mandate is defined as receipt prior to 23 August 2021, post-mandate is defined as on or after 23 August 2021.

^dIncludes only those who completed a two-dose primary series. ^ePrimary series completion in the recommended timing was defined as

 \leq 56 days between the first and second dose; late is defined as >56 days between the first and second dose.

ADSMs, active duty Service members; IQR, interquartile range.

	All	California	Texas	Virginia	North Carolina	Georgia	Florida	Washington
	N=1,594,948	N=188,409	N=145,636	N=134,679	N=107,025	N=73,745	N=77,121	N=68,974
	Univariate							
	OR (95% CI)							
Age								
17-49	Ref							
50-65	2.46 (2.38- 2.54)	2.97 (2.55- 3.47)	2.35 (2.13- 2.60)	3.70 (3.19- 4.28)	3.19 (2.70- 3.78)	1.51 (1.32- 1.72)	3.14 (2.66- 3.71)	1.75 (1.39- 2.21)
Sex	,					,		
Male	Ref							
Famala	1.04 (1.03-	1.16 (1.13-	1.00 (0.97-	0.94 (0.91-	1.20 (1.16-	0.91 (0.87-	1.02 (0.98-	0.89 (0.84-
Female	1.05)	1.20)	1.03)	0.97)	1.26)	0.96)	1.06)	0.93)
Race								
American	1 06 (1 02-	1 13 (1 03-	0.99 (0.87-	1 00 (0 89-	1.08 (0.94-	1 18 (0.96-	1 12 (0.96-	1 00 (0 84-
Indian or	1.00 (1.02-	1.13 (1.05-	1 12)	1.00 (0.0)-	1.00 (0.94-	1.10 (0.90-	1.12 (0.90-	1.00 (0.04-
Alaska Native	1.10)	1.27)	1.12)	1.15)	1.23)	1.15)	1.51)	1.20)
Asian or Pacific	2.02 (1.98-	2.17 (2.06-	1.97 (1.86-	1.75 (1.63-	1.83 (1.70-	1.64 (1.50-	1.79 (1.63-	1.69 (1.54-
Islander	2.05)	2.28)	2.09)	1.89)	1.97)	1.80)	1.96)	1.84)
Black or	0.75 (0.74-	0.85 (0.82-	0.75 (0.73-	0.67 (0.65-	0.89 (0.86-	0.66 (0.64-	0.68 (0.66-	0.67 (0.63-
African	0.76)	0.87)	0.78)	0.69)	0.92)	0.69)	0.71)	0.70)
American	Def	Def	D - f	D - f	D - f	D - f	D - f	D of
white	Kei 1 24 (1 22	Kei	Ref	Ref	Ref	Ref	Ref	Kei
Other	1.34 (1.32-	1.50 (1.48-	1.03 (0.67-	1.09 (1.03-	1.20 (1.10-	0.96 (0.87-	1.31 (1.23-	1.10 (1.00-
Ilianania	1.37)	1.03)	1.10)	1.14)	1.51)	1.07)	1.40)	1.21)
Ethnicity								
	1 03 (1 02	0.86 (0.84	1 10 (1 07	1.01.(0.97	0.06 (0.02	1 10 (1 05	1.02 (0.97	1.07 (1.02
Yes	1.03 (1.02-	0.00 (0.04-	1.10 (1.0/-	1.01 (0.97-	0.90 (0.93-	1.10 (1.05-	1.02 (0.97-	1.07 (1.02 - 1.14)
No	R ef	Ref	Ref	Ref	Ref	Ref	Ref	1.14) Ref
110	1.01	1.01	1.01	1.01	1.01	1.01	1.01	1.01

Table 2. Unadjusted odds of initiating the primary vaccine series prior to the DoD mandate, overall and in select states of residence^a

Branch of Service								
Air Force	0.88 (0.87- 0.89)	1.02 (0.97- 1.07)	0.66 (0.64- 0.67)	1.16 (1.20-1.23)	0.79 (0.46- 0.52)	0.91 (0.87-0.96)	0.93 (0.89- 0.98)	0.43 (0.41- 0.56)
Army	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Coast Guard	1.54 (1.50- 1.58)	2.14 (1.95- 2.35)	1.05 (0.93- 1.17)	1.93 (1.76- 2.12)	0.72 (0.64- 0.81)	1.22 (0.99- 1.52)	1.83 (0.69- 1.99)	1.25 (1.08- 1.45)
Marine Corps	0.58 (0.57- 0.59)	0.65 (0.62- 0.68)	0.69 (0.64- 0.74)	0.79 (0.75- 0.83)	0.30 (0.30- 0.31)	0.71 (0.63- 0.79)	0.91 (0.85- 0.98)	0.57 (0.49- 0.67)
Navy	1.54 (1.52- 1.55)	1.87 (1.80- 1.96)	0.92 (0.87- 0.97)	1.42 (1.37- 1.47)	0.86 (0.80- 0.93)	1.68 (1.58- 1.80)	1.67 (1.59- 1.75)	1.38 (1.32- 1.45)
Rank								
Enlisted	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Officer	4.28 (4.22 - 4.35)	5.32 (5.02- 5.63)	3.94 (3.76- 4.13)	4.41 (4.17- 4.65)	5.59 (5.25- 5.95)	3.01 (2.83- 3.20)	4.67 (4.41- 4.94)	3.89 (3.54- 4.28)
Warrant Officer	2.03 (1.96- 2.10)	2.61 (2.23- 3.06)	1.81 (1.65-1.99)	2.41 (2.08- 2.78)	2.52 (2.23- 2.86)	2.01 (1.73- 2.32)	2.76 (2.23- 3.41)	1.98 (1.61- 2.45)
COVID infection prior to initiating primary series								
Lab confirmed	0.55 (0.54- 0.55)	0.57 (0.55- 0.59)	0.69 (0.66- 0.72)	0.58 (0.56- 0.61)	0.51 (0.49- 0.53)	0.56 (0.53- 0.58)	0.49 (0.57- 0.52)	0.43 (0.40- 0.46)
ICD-10-CM	0.51 (0.50-	0.57 (0.54-	0.71 (0.68-	0.42 (0.39-	0.72 (0.67-	0.59 (0.54-	0.34 (0.32-	0.40 (0.36-
defined	0.52)	0.61)	0.74)	0.45)	0.76)	0.63)	0.36)	0.44)
No	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref

Bold text indicates a significant difference from the reference category at P<0.05.

OR, odds ratio; CI, confidence interval; Ref, reference group.

	All	California	Texas	Virginia	North Carolina	Georgia	Florida	Washington
	N=415,359	N=40,689	N=30,439	N=38,632	N=16,341	N=12,957	N=17,822	N=17,678
Age								
17-49	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
50-65	-18.78 (-19.59, -17.96)	-18.46 (-21.73, -15.18)	-11.85 (-14.57, -9.14)	-25.88 (-28.98, -22.79)	-18.00 (- 22.71, - 13.28)	-13.78 (- 18.21, - 9.36)	-18.05 (- 22.35, - 13.75)	-23.52 (- 28.53, - 18.50)
Sex								(
Male	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Female	-5.93 (-6.33, - 5.53)	-3.92 (-5.18, - 2.66)	-5.98 (-7.40, - 4.56)	-6.99 (-8.56, - 5.41)	-5.27 (- 7.66, -2.88)	-5.68 (- 8.13, -3.22)	-5.25 (-7.30, -3.21)	-5.93 (-7.87, -3.98)
Race		,	,	,				
American Indian or Alaska Native	4.23 (2.58, 5.87)	4.95 (0.72, 9.17)	6.17 (-0.65, 13.00)	3.50 (-2.36, 9.36)	-0.69 (- 9.89, 8.50)	7.00 (-4.43, 18.44)	4.33 (-3.71, 12.28)	6.28 (-0.22, 12.77)
Asian or Pacific	-0.27 (-0.52,	0.82 (-2.28,	-1.06 (-3.12,	-1.12 (-3.70,	1.45 (-2.01,	-4.57 (-	-0.74 (-4.31,	1.91 (-0.54,
Islander	0.32)	0.93)	1.00)	1.47)	4.91)	8.41, -0.72)	2.84)	4.36)
Black or African	-0.25 (-0.72,	0.51 (-1.05,	-1.63 (-3.22, -	0.90 (-0.84,	0.58 (-1.92,	-5.49 (-	-0.23 (-0.61,	4.67 (2.27,
American	0.22)	2.07)	0.03)	2.63)	3.08)	7.94, -3.04)	2.16)	7.07)
White	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Other	-0.81 (-1.47, - 0.16)	0.52 (-1.25, 2.30)	-6.55 (-9.41, - 3.68)	2.75 (0.35, 5.14)	-1.54 (- 6.18, 3.10)	1.97 (-2.80, 6.74)	-0.51 (-3.48, 2.46)	3.21 (0.09, 6.32)
Hispanic Ethnicity								
Yes	4.20 (3.76, 4.65)	3.21 (1.95, 4.46)	3.36 (1.89, 4.82)	5.19 (3.32, 7.06)	4.77 (3.38, 7.16)	3.54 (0.83, 6.25)	1.40 (-0.87, 3.66)	5.72 (3.65, 7.80)
No	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Branch of Service								
Air Force	0.69 (0.28,	12.04 (9.95,	-8.08 (-9.42, -	1.25 (-1.48,	-0.02 (-	2.70 (0.22,	6.04 (3.00,	0.29 (-2.24,
	1.10)	14.14)	6.73)	3.97)	3.28, 3.25)	5.19)	9.08)	2.82)
Army	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref

Table 3. Unadjusted difference in the mean days between booster eligibility and receipt, overall and in select states of residence

Coast Guard	-6.72 (-7.73, - 5.71)	7.66 (4.75, 10.57)	1.60 (-4.54, 7.74)	0.73 (-3.20, 4.67)	-13.00 (- 19.41, - 6.59)	-11.53 (- 23.78, 0.71)	11.23 (6.59, 15.86)	-24.32 (- 29.31, - 19.33)
Marine Corps	18.21 (17.51, 18.91)	30.08 (27.96, 32.20)	0.91 (-4.86, 6.68)	30.45 (27.14, 33.76)	3.96 (1.97, 5.95)	3.95 (-5.93, 13.82)	6.70 (1.04, 12.34)	24.95 (9.64, 40.26)
Navy	7.74 (7.33, 8.16)	23.22 (21.36, 25.07)	0.01 (-2.69, 2.70)	18.76 (16.90, 20.62)	-3.43 (- 6.77, -0.09)	21.58 (18.92, 24.23)	11.25 (8.32, 14.18)	6.62 (5.00, 8.25)
Rank								
Enlisted	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref
Officer	-16.13 (-16.49, -15.78)	-15.24 (-16.39, -14.10)	-12.35 (-13.64, -11.07)	-24.25 (-25.66, -22.84)	-11.23 (- 13.12, - 9.35)	-9.17 (- 11.27, - 7.08)	-12.95 (- 14.70, 11.21)	-17.51 (- 19.23, - 15.79)
Warrant Officer	-7.86 (-9.01, - 6.71)	-9.22 (-13.59, - 4.86)	-2.17 (-5.82, 1.48)	-15.38 (-20.03, -10.74)	-6.04 (- 11.22, - 0.86)	-4.61 (- 10.14, 0.93)	-4.38 (- 11.78, 3.01)	-7.98 (- 13.22, - 2.75)
COVID infection between primary series and booster								
Lab confirmed	40.72 (40.07, 41.36)	37.89 (35.85, 39.93)	40.03 (37.83, 42.23)	47.32 (44.08, 50.55)	40.68 (37.67, 43.69)	39.35 (35.75, 42.96)	45.78 (42.20, 49.15)	34.38 (31.47, 37.29)
ICD-10-CM defined	22.49 (21.61, 23.37)	22.98 (19.64, 26.32)	16.93 (13.84, 20.03)	29.67 (26.17, 33.18)	20.29 (14.93, 25.65)	23.71 (18.40, 29.03)	30.83 (27.05, 34.61)	25.17 (20.91, 29.44)
No	Ref	Ref	Ref	Ref	Ref	Ref	Ref	Ref

Bold text indicates a significant difference from the reference category at P<0.05.

Ref, reference group.

Active duty Service members receiving the first COVID-19 primary series dose per month

